GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Korea Arlico Pharm Co Ltd (XKRX:260660) » Definitions » EV-to-Revenue

Korea Arlico Pharm Co (XKRX:260660) EV-to-Revenue : 0.47 (As of Jan. 18, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Korea Arlico Pharm Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Korea Arlico Pharm Co's enterprise value is ₩85,064 Mil. Korea Arlico Pharm Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ₩182,558 Mil. Therefore, Korea Arlico Pharm Co's EV-to-Revenue for today is 0.47.

The historical rank and industry rank for Korea Arlico Pharm Co's EV-to-Revenue or its related term are showing as below:

XKRX:260660' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.31   Med: 0.89   Max: 2.36
Current: 0.46

During the past 9 years, the highest EV-to-Revenue of Korea Arlico Pharm Co was 2.36. The lowest was 0.31. And the median was 0.89.

XKRX:260660's EV-to-Revenue is ranked better than
92.91% of 987 companies
in the Drug Manufacturers industry
Industry Median: 2.38 vs XKRX:260660: 0.46

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-01-18), Korea Arlico Pharm Co's stock price is ₩3615.00. Korea Arlico Pharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₩15,009.75. Therefore, Korea Arlico Pharm Co's PS Ratio for today is 0.24.


Korea Arlico Pharm Co EV-to-Revenue Historical Data

The historical data trend for Korea Arlico Pharm Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korea Arlico Pharm Co EV-to-Revenue Chart

Korea Arlico Pharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 1.06 0.98 0.71 0.58 0.54

Korea Arlico Pharm Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.54 0.55 0.57 0.50

Competitive Comparison of Korea Arlico Pharm Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Korea Arlico Pharm Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korea Arlico Pharm Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Korea Arlico Pharm Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Korea Arlico Pharm Co's EV-to-Revenue falls into.



Korea Arlico Pharm Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Korea Arlico Pharm Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=85064.284/182557.941
=0.47

Korea Arlico Pharm Co's current Enterprise Value is ₩85,064 Mil.
Korea Arlico Pharm Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩182,558 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korea Arlico Pharm Co  (XKRX:260660) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Korea Arlico Pharm Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3615.00/15009.745
=0.24

Korea Arlico Pharm Co's share price for today is ₩3615.00.
Korea Arlico Pharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩15,009.75.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korea Arlico Pharm Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Korea Arlico Pharm Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Korea Arlico Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
7-21, Baumoe-ro 27-gil, Seocho-gu, Seoul, KOR
Korea Arlico Pharm Co Ltd is engaged in the business of manufacturing and selling pharmaceuticals products. The company offers products in the area of the circulatory system, antiplatelet, muscle relaxants, diabetes, antibiotic and chemotherapy, allergy and respiratory disease, ointment, vitamin and health supplements, digestive system, and metabolic disease. It provides products in various forms such as tablets, capsules, gel, and cream.

Korea Arlico Pharm Co Headlines

No Headlines